G. Patel

发表

Expression of the 35kDa and low molecular weight surfactant-associated proteins in the lungs of infants dying with respiratory distress syndrome.

J. Floros, D. Demello, D. Lagunoff, 1989, The American journal of pathology.

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan

H. Kupper, T. Kawai, K. Yamaguchi, 2012, Clinical Rheumatology.

Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects

J. Wade, M. Sumeray, S. Dutta, 2016, Journal of clinical pharmacology.

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria

B. Schweighardt, K. Larimore, B. Burton, 2021, Clinical and translational science.

Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment

J. Bruss, K. Rodvold, Vipul K. Gupta, 2022, Antimicrobial agents and chemotherapy.

Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.

P. Hari, A. Szabo, A. D’Souza, 2019, Hematology/oncology and stem cell therapy.

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years

B. Bader-Meunier, H. Kupper, V. Arora, 2014, Clinical Rheumatology.

Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects

L. Gasink, A. Talley, Y. Lei, 2023, Antimicrobial agents and chemotherapy.

Laser‐ablated nanofunctional polymers for the formulation of slow‐release powders for dry powder inhalers: physicochemical characterization and slow‐release characteristics

R. Singh, V. Craciun, J. Rocca, 2007, The Journal of pharmacy and pharmacology.